MARIA CASSIA JACINTHO MENDES CORREA

(Fonte: Lattes)
Índice h a partir de 2011
21
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/52 - Laboratório de Virologia, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2014 ×

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • article 16 Citação(ões) na Scopus
    Prevalence, risk factors and genotypes of hepatitis B infection among HIV-infected patients in the State of MS, Central Brazil
    (2014) FREITAS, Solange Zacalusni; SOARES, Caroline Cordeiro; TANAKA, Tayana Serpa Ortiz; LINDENBERG, Andrea Siqueira Campos; TELES, Sheila Araujo; TORRES, Marina Satuada; MELLO, Francisco Campello Amaral; MENDES-CORREA, Maria Cassia; SAVASSI-RIBAS, Flavia; MOTTA-CASTRO, Ana Rita Coimbra
    Objective: A cross-sectional study on prevalence of HBV and HDV infection, risk factors and genotype distribution of HBV infection was conducted among 848 HIV-infected patients in Mato Grosso do Sul, Central Brazil. Methods: Serum samples of 848 participants were tested for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) and hepatitis surface antibody (anti-HBs). HBsAg positive samples were tested for anti-HBc IgM, HBeAg, anti-HBe, anti-HCV, and total anti-HDV. HBsAg and anti-HBc positive were subjected to DNA extraction. Viral DNA was amplified by semi-nested PCR for the regions pre-S/S and then purified and genotyped/subgenotyped by direct sequencing. Student's t-test, chi-square test and Fisher's exact test were used to compare variables and to evaluate association between HBV positivity (defined as anti-HBc and/or HBsAg positivity) and risk factors. Results: Among the 848 HIV infected patients investigated 222 had serological markers of HBV infection. The prevalence rate of HIV-HBV coinfection was 2.5% (21/848; 95% CI: 1.4-3.5%); 484 (57.1%) patients were susceptible for HBV infection. There were no cases of anti-HDV positive and only one (0.1%) anti-HCV-positive case among the HIV-HBV coinfected patients. Male gender, increasing age, family history of hepatitis, use of illicit drug, and homosexual activity were independent factors associated with HBV exposure. The phylogenetic analysis based on the S gene region revealed the presence of genotypes D (76.9%), F (15.4%) and A (7.7%) in the study sample. Conclusion: This study demonstrates the low prevalence of HIV-HBV infection and also highlights the need for early vaccination against HBV as well as testing for HBV, HCV and HDV in all HIV-infected individuals.
  • article 234 Citação(ões) na Scopus
    Historical epidemiology of hepatitis C virus (HCV) in selected countries
    (2014) BRUGGMANN, P.; BERG, T.; OVREHUS, A. L. H.; MORENO, C.; MELLO, C. E. Brandao; ROUDOT-THORAVAL, F.; MARINHO, R. T.; SHERMAN, M.; RYDER, S. D.; SPERL, J.; AKARCA, U.; BALIK, I.; BIHL, F.; BILODEAU, M.; BLASCO, A. J.; BUTI, M.; CALINAS, F.; CALLEJA, J. L.; CHEINQUER, H.; CHRISTENSEN, P. B.; CLAUSEN, M.; COELHO, H. S. M.; CORNBERG, M.; CRAMP, M. E.; DORE, G. J.; DOSS, W.; DUBERG, A. S.; EL-SAYED, M. H.; ERGOR, G.; ESMAT, G.; ESTES, C.; FALCONER, K.; FELIX, J.; FERRAZ, M. L. G.; FERREIRA, P. R.; FRANKOVA, S.; GARCIA-SAMANIEGO, J.; GERSTOFT, J.; GIRIA, J. A.; GONCALES JR., F. L.; GOWER, E.; GSCHWANTLER, M.; PESSOA, M. Guimaraes; HEZODE, C.; HOFER, H.; HUSA, P.; IDILMAN, R.; KABERG, M.; KAITA, K. D. E.; KAUTZ, A.; KAYMAKOGLU, S.; KRAJDEN, M.; KRARUP, H.; LALEMAN, W.; LAVANCHY, D.; LAZARO, P.; MAROTTA, P.; MAUSS, S.; CORREA, M. C. Mendes; MUELLHAUPT, B.; MYERS, R. P.; NEGRO, F.; NEMECEK, V.; ORMECI, N.; PARKES, J.; PELTEKIAN, K. M.; RAMJI, A.; RAZAVI, H.; REIS, N.; ROBERTS, S. K.; ROSENBERG, W. M.; SARMENTO-CASTRO, R.; SARRAZIN, C.; SEMELA, D.; SHIHA, G. E.; SIEVERT, W.; STARKEL, P.; STAUBER, R. E.; THOMPSON, A. J.; URBANEK, P.; THIEL, I. van; VLIERBERGHE, H. Van; VANDIJCK, D.; VOGEL, W.; WAKED, I.; WEDEMEYER, H.; WEIS, N.; WIEGAND, J.; YOSRY, A.; ZEKRY, A.; DAMME, P. Van; ALEMAN, S.; HINDMAN, S. J.
    Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6358000 cases in 2008 and Brazil with 2106000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.
  • article 182 Citação(ões) na Scopus
    Strategies to manage hepatitis C virus (HCV) disease burden
    (2014) WEDEMEYER, H.; DUBERG, A. S.; BUTI, M.; ROSENBERG, W. M.; FRANKOVA, S.; ESMAT, G.; ORMECI, N.; VLIERBERGHE, H. Van; GSCHWANTLER, M.; AKARCA, U.; ALEMAN, S.; BALIK, I.; BERG, T.; BIHL, F.; BILODEAU, M.; BLASCO, A. J.; MELLO, C. E. Brandao; BRUGGMANN, P.; CALINAS, F.; CALLEJA, J. L.; CHEINQUER, H.; CHRISTENSEN, P. B.; CLAUSEN, M.; COELHO, H. S. M.; CORNBERG, M.; CRAMP, M. E.; DORE, G. J.; DOSS, W.; EL-SAYED, M. H.; ERGOR, G.; ESTES, C.; FALCONER, K.; FELIX, J.; FERRAZ, M. L. G.; FERREIRA, P. R.; GARCIA-SAMANIEGO, J.; GERSTOFT, J.; GIRIA, J. A.; GONCALES JR., F. L.; PESSOA, M. Guimaraes; HEZODE, C.; HINDMAN, S. J.; HOFER, H.; HUSA, P.; IDILMAN, R.; KABERG, M.; KAITA, K. D. E.; KAUTZ, A.; KAYMAKOGLU, S.; KRAJDEN, M.; KRARUP, H.; LALEMAN, W.; LAVANCHY, D.; LAZARO, P.; MARINHO, R. T.; MAROTTA, P.; MAUSS, S.; CORREA, M. C. Mendes; MORENO, C.; MUELLHAUPT, B.; MYERS, R. P.; NEMECEK, V.; OVREHUS, A. L. H.; PARKES, J.; PELTEKIAN, K. M.; RAMJI, A.; RAZAVI, H.; REIS, N.; ROBERTS, S. K.; ROUDOT-THORAVAL, F.; RYDER, S. D.; SARMENTO-CASTRO, R.; SARRAZIN, C.; SEMELA, D.; SHERMAN, M.; SHIHA, G. E.; SPERL, J.; STARKEL, P.; STAUBER, R. E.; THOMPSON, A. J.; URBANEK, P.; DAMME, P. Van; THIEL, I. van; VANDIJCK, D.; VOGEL, W.; WAKED, I.; WEIS, N.; WIEGAND, J.; YOSRY, A.; ZEKRY, A.; NEGRO, F.; SIEVERT, W.; GOWER, E.
    The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
  • article 346 Citação(ões) na Scopus
    The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
    (2014) RAZAVI, H.; WAKED, I.; SARRAZIN, C.; MYERS, R. P.; IDILMAN, R.; CALINAS, F.; VOGEL, W.; CORREA, M. C. Mendes; HEZODE, C.; LAZARO, P.; AKARCA, U.; ALEMAN, S.; BALIK, I.; BERG, T.; BIHL, F.; BILODEAU, M.; BLASCO, A. J.; MELLO, C. E. Brandao; BRUGGMANN, P.; BUTI, M.; CALLEJA, J. L.; CHEINQUER, H.; CHRISTENSEN, P. B.; CLAUSEN, M.; COELHO, H. S. M.; CRAMP, M. E.; DORE, G. J.; DOSS, W.; DUBERG, A. S.; EL-SAYED, M. H.; ERGOR, G.; ESMAT, G.; FALCONER, K.; FELIX, J.; FERRAZ, M. L. G.; FERREIRA, P. R.; FRANKOVA, S.; GARCIA-SAMANIEGO, J.; GERSTOFT, J.; GIRIA, J. A.; GONCALES JR., F. L.; GOWER, E.; GSCHWANTLER, M.; PESSOA, M. Guimaraes; HINDMAN, S. J.; HOFER, H.; HUSA, P.; KABERG, M.; KAITA, K. D. E.; KAUTZ, A.; KAYMAKOGLU, S.; KRAJDEN, M.; KRARUP, H.; LALEMAN, W.; LAVANCHY, D.; MARINHO, R. T.; MAROTTA, P.; MAUSS, S.; MORENO, C.; MURPHY, K.; NEGRO, F.; NEMECEK, V.; ORMECI, N.; OVREHUS, A. L. H.; PARKES, J.; PASINI, K.; PELTEKIAN, K. M.; RAMJI, A.; REIS, N.; ROBERTS, S. K.; ROSENBERG, W. M.; ROUDOT-THORAVAL, F.; RYDER, S. D.; SARMENTO-CASTRO, R.; SEMELA, D.; SHERMAN, M.; SHIHA, G. E.; SIEVERT, W.; SPERL, J.; STARKEL, P.; STAUBER, R. E.; THOMPSON, A. J.; URBANEK, P.; DAMME, P. Van; THIEL, I. van; VLIERBERGHE, H. Van; VANDIJCK, D.; WEDEMEYER, H.; WEIS, N.; WIEGAND, J.; YOSRY, A.; ZEKRY, A.; CORNBERG, M.; MUELLHAUPT, B.; ESTES, C.
    The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
  • article 28 Citação(ões) na Scopus
    High prevalence of hepatitis B virus subgenotypes A1 and D4 in Maranhao state, Northeast Brazil
    (2014) BARROS, Lena Maria Fonseca; GOMES-GOUVEA, Michele Soares; KRAMVIS, Anna; MENDES-CORREA, Maria Cassia Jacintho; SANTOS, Alexsandro dos; SOUZA, Leticia Alana Barros; SANTOS, Max Diego Cruz; CARRILHO, Flair Jose; DOMICINI, Arnaldo de Jesus; PINHO, Joao Renato Rebello; FERREIRA, Adalgisa de Souza Paiva
    In this study, we determined the prevalence of HBV subgenotypes in Maranhao state, located in northeastern Brazil, where the population is heterogeneous, with a high proportion of African descendants. HBV was detected in 119 of 133 (89.5%) chronic hepatitis B patients, including 103 (86.5%) who were HBeAg-negative. Using phylogenetic analysis of the S/Polymerase region of HBV DNA, subgenotype A1 was found to be the most prevalent (67%), followed by genotype D (28%; subgenotype D4 was detected in 24%, D3 in 3%, and D2 in 1%). Genotype F, clustering with subgenotype F2a, was found in six (5%) patients. The topology of the phylogenetic tree showed that HBV/A1 sequences did not cluster together, suggesting that more than one strain was introduced into Maranhao. On the other hand, HBV/D4 sequences formed a monophyletic cluster, suggesting a single entry of this strain in this population. This study showed that HBV/A1 was the only subgenotype of HBV/A present in the population from Maranhao and indicated that in this region HBV/A1 was not restricted to an Afro-descendant community where it was previously reported, but is widely distributed among general population of HBV chronic carriers. Unexpectedly, we found a high frequency of HBV subgenotype D4. Together with previously reported data on the distribution of HBV/D4 in the world, these findings suggest that this subgenotype was more prevalent in the African continent in the past and may have been introduced in Maranhao by means of the slave trade during the late XVIII century, when the largest number of African slaves arrived to this region.